Ana Alarcon Tomas

Modified-EASIX predicts severe cytokine release syndrome and neurotoxicity after Chimeric Antigen Receptor (CAR) T cells.

M. Perales, S. Devlin, R. Brentjens, 2021, Blood advances.

Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma

M. Perales, A. Nagler, S. Devlin, 2022, Leukemia.

The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant

M. Perales, S. Devlin, S. Giralt, 2021, Bone Marrow Transplantation.

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy

G. Salles, M. Perales, M. V. D. van den Brink, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation.

Daigo Hashimoto, Robert R Jenq, Amy Bush, 2020, The New England journal of medicine.

Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma

M. Perales, Karthik D Nath, K. Wudhikarn, 2023, Expert opinion on drug safety.

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

P. Riedell, M. Perales, D. Porter, 2022, Blood advances.

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

P. Riedell, M. Gonen, M. Perales, 2022, Blood.

Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma

M. Perales, S. Devlin, P. Hamlin, 2023, Blood advances.

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

P. Riedell, M. Gonen, M. Perales, 2023, Blood advances.